Skip to main content

Table 3 Trial procedures and Timelines

From: A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial

Weeks

Screening (− 30 days)

Baseline (FV)

4

12

24 (FV)

28

36

48 (FV)

Early termination visit (FV)

30 day post treatment follow up

(telephone call or standard of care clinic visit)

Informed consent

X

         

Demographic data and medical history including full ART history

X

         

Eligibility criteria

X

X

        

Review of historical drug resistance tests

X

         

Adverse events

 

X

X

X

X

X

X

X

X

X

Concomitant medications

X

X

X

X

X

X

X

X

X

X

HIV-SI

 

X

  

X

  

X

X

 

PSQI

 

X

  

X

  

X

X

 

HIV associated conditions

X

X

X

X

X

X

X

X

X

X

Randomisation

 

X

        

e-Case Report Forms

X

X

X

X

X

X

X

X

X

X

Vital signs (Blood Pressure, Pulse, temperature, weight)

X

X

X

 

X

X

 

X

X

 

Complete/asymptom directed physical examination

X

Xa

Xa

Xa

Xa

Xa

Xa

Xa

Xa

 

Height

X

         

Weight, BMI & waist circumference

X

X

X

 

X

X

 

X

X

 

12 Lead ECG

X

   

X

  

X

X

 

Urinalysis

X

X

X

 

X

X

 

X

X

 

Urine Pregnancy Test

X

X

X

 

X

X

 

X

X

 

CD4/CD8 T cell count

 

X

  

X

  

X

X

 

HIV-1 RNA viral load (& resistance testing if > 50 copies/mL)

X

X

X

X

X

X

X

X

X

 

Whole blood for Proviral DNA

 

X

        

Haematology

X

X

X

 

X

X

 

X

X

 

Urea, electrolytes, creatinine, phosphate, glucose, calcium, amylase

X

X

X

 

X

X

 

X

X

 

Estimated GFR

X

X

X

 

X

X

 

X

X

 

UPCR

X

X

X

 

X

X

 

X

X

 

HBV & HCV serology

X

         

Liver function tests

X

X

X

 

X

X

 

X

X

 

Lipids (Fasting Cholesterol, LDL, HDL, Triglycerides)

 

X

  

X

  

X

X

 

HbA1c

 

X

  

X

  

X

X

 

Pill count adherence

 

X

X

X

X

X

X

X

X

 

Self-reported adherence

 

X

X

X

X

X

X

X

X

 

Study drug dispensation

 

X

X

X

X

X

X

   

Study drug accountability

  

X

X

X

X

X

X

X

 
  1. FV Fasting visit, HIV-SI HIV symptom distress module, PSQI Pittsburgh Sleep Quality Index, BMI Body mass index, UPCR urine protein creatinine ratio, HBV Hepatitis B virus, HCV Hepatitis C virus, LDL Low density lipoprotein, HDL High density lipoprotein